MCID: BRD004
MIFTS: 46

Borderline Personality Disorder malady

Category: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

About this section

Aliases & Descriptions for Borderline Personality Disorder:

Name: Borderline Personality Disorder 11 49 38 13 67

Classifications:



External Ids:

Disease Ontology11 DOID:10930
ICD1029 F60.3
ICD9CM31 301.83
SNOMED-CT61 192488005, 20010003
MeSH38 D001883
NCIt44 C92633

Summaries for Borderline Personality Disorder

About this section
Disease Ontology:11 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary: Borderline Personality Disorder is related to intermittent explosive disorder and cocaine dependence. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways are noradrenaline and adrenaline degradation and Dopamine metabolism. Affiliated tissues include brain, amygdala and bone, and related mouse phenotypes are integument and muscle.

Wikipedia:70 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder, is a... more...

Related Diseases for Borderline Personality Disorder

About this section

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 116)
idRelated DiseaseScoreTop Affiliating Genes
1intermittent explosive disorder30.1MAOA, SLC6A4
2cocaine dependence29.7BDNF, HTR1B, MAOA
3dysthymic disorder28.7BDNF, HTR1B, HTR2A, HTR2C, SLC6A4
4avoidant personality disorder28.1BDNF, COMT, HTR1A, HTR2A, HTR2C, MAOA
5schizophrenia26.9BDNF, COMT, HTR1A, HTR1B, HTR2A, HTR2C
6obsessive-compulsive personality disorder26.0BDNF, COMT, HTR1A, HTR1B, HTR2A, HTR2C
7personality disorder11.1
8sexual sadism10.8
9impulse control disorder10.8
10thyroid cancer, childhood10.5COMT, TPH1
11intrahepatic gall duct cancer10.5MAOA, SLC6A4
12ring chromosome 14 syndrome10.5COMT, MAOA
13rabies10.4MAOA, SLC6A4
14glutathionuria10.4COMT, TPH1
15splenic disease10.4HTR2A, SLC6A4
16paranoid personality disorder10.4HTR1A, HTR2A
17vasculitis10.4HTR1A, HTR2A
18lipedematous scalp10.4COMT, HTR2A
19ulcerative colitis10.3BDNF, COMT, SLC6A4
20hemorrhagic cystitis10.3COMT, MAOA, SLC6A4
21herpes gestationis10.3HTR1A, HTR2A
22pervasive developmental disorder10.3BDNF, COMT, SLC6A4
23tongue disease10.3COMT, MAOA, SLC6A4
24transsexualism10.3BDNF, HTR1A
25neurodegeneration with optic atrophy, childhood onset10.3COMT, HTR2A, SLC6A4
26anosognosia10.3COMT, HTR1A, SLC6A4
27lymphadenitis10.3BDNF, MAOA, SLC6A4
28nonencapsulated sclerosing carcinoma10.3HTR1A, MAOA, SLC6A4
29pyromania10.3HTR1A, MAOA, SLC6A4
30malignant peripheral nerve sheath tumor10.3HTR1A, MAOA, SLC6A4
31bipolar disorder10.2
32kunjin encephalitis10.2TPH1, TPH2
33measles10.2COMT, TPH1
34chagas disease10.2HTR2A, MAOA, SLC6A4
35histiocytoid hemangioma10.2COMT, TPH1
36kernicterus due to isoimmunization10.2HTR1A, HTR2A
37tinea pedis10.2HTR1A, HTR1B, SLC6A4
38bulimia nervosa10.1
39vascular cancer10.1HTR1A, HTR2A
40phlegmonous dacryocystitis10.1COMT, MAOA, SLC6A4, TPH1
41substance dependence10.1
42attention deficit-hyperactivity disorder10.1
43autoimmune-related retinopathy and optic neuropathy10.1HTR2A, SLC6A4, TPH2
44antisocial personality disorder10.0
45mood disorder10.0
46somatoform disorder10.0
47eating disorder10.0
48acatalasemia10.0BDNF, COMT, HTR2A, SLC6A4
49sick sinus syndrome10.0HTR1A, HTR2A
50alexithymia10.0

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Hypertension, EssentialMajor Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment
Dependent Personality DisorderSchizophreniform Disorder
Dysthymic DisorderCerebral Atherosclerosis
Acute CystitisHypothyroidism
Anxiety Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to borderline personality disorder

Symptoms for Borderline Personality Disorder

About this section

Drugs & Therapeutics for Borderline Personality Disorder

About this section

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 109)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 2375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
Fluoxetineapproved, vet_approvedPhase 423554910-89-33386
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
AKOS003663021
Adofen
Animex-On
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
Bio-0787
Biomol-NT_000152
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine Hcl
Fluoxetine Hydrochloride
Fluoxetine [USAN:INN:BAN]
Fluoxetinum
 
Fluoxetinum [INN-Latin]
Fluoxétine
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
LS-31040
Lilly-110140
Lopac0_000558
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
SPBio_001815
SPBio_002382
STK734483
Sarafem
SpecPlus_000723
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
Spectrum_001679
TL8003595
UNII-01K63SUP8D
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
fluoxetine
fluoxetine (Prozac)
nchembio.534-comp2
3
Risperidoneapproved, investigationalPhase 4487106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
 
NCGC00015883-01
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
4
CitalopramapprovedPhase 4, Phase 250359729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
5
Lamotrigineapproved, investigationalPhase 418384057-84-13878
Synonyms:
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine
6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
84057-84-1
AC-10298
AC1L1GWT
BIDD:GT0794
BW 430C
BW-430C
Bio-0056
C047781
CHEBI:138727
CHEBI:6367
CHEMBL741
CID3878
CPD000058464
Crisomet
D00354
DB00555
Desitin Brand of Lamotrigine
EINECS 281-901-8
EU-0100688
EUR-1048
Faes Brand of Lamotrigine
GI 267119X
GW 273293
Glaxo Wellcome Brand of Lamotrigine
GlaxoSmithKline Brand of Lamotrigine
HMS2051C10
HMS2089M08
HMS2093P21
HSDB 7526
Juste Brand of Lamotrigine
L 3791
L3791_SIGMA
LS-155249
 
Labileno
Lamictal
Lamictal (TN)
Lamictal CD
Lamictal Cd
Lamictal ODT
Lamictal XR
Lamictin
Lamiktal
Lamitor
Lamotrigina
Lamotrigina [Spanish]
Lamotrigine
Lamotrigine (JAN/USAN/INN)
Lamotrigine [USAN:INN:BAN]
Lamotriginum
Lamotriginum [Latin]
Lopac-L-3791
Lopac0_000688
MLS000069685
MLS000759486
MLS001077325
MolPort-003-666-744
NCGC00015605-01
NCGC00015605-02
NCGC00015605-06
NCGC00015605-08
NCGC00022936-02
NCGC00022936-04
NCGC00022936-05
NSC746307
SAM001246697
SMP2_000303
SMR000058464
STK628377
Tocris-1611
UNII-U3H27498KS
ZINC00013156
lamotrigine
6Serotonin Uptake InhibitorsPhase 4, Phase 3, Phase 21570
7Serotonin AgentsPhase 4, Phase 3, Phase 23102
8
SerotoninPhase 4, Phase 3, Phase 2356650-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
9Psychotropic DrugsPhase 4, Phase 3, Phase 26279
10Tranquilizing AgentsPhase 4, Phase 3, Phase 24164
11Dopamine AgentsPhase 4, Phase 23759
12Central Nervous System DepressantsPhase 4, Phase 3, Phase 212806
13Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 222776
14Antipsychotic AgentsPhase 4, Phase 3, Phase 22359
15Serotonin AntagonistsPhase 4, Phase 21381
16Dopamine AntagonistsPhase 4, Phase 21083
17Autonomic AgentsPhase 4, Phase 3, Phase 29774
18Antiparkinson AgentsPhase 4, Phase 21527
19Cholinergic AgentsPhase 4, Phase 23846
20Cytochrome P-450 Enzyme InhibitorsPhase 43822
21Cholinergic AntagonistsPhase 4, Phase 21658
22Antidepressive Agents, Second-GenerationPhase 4, Phase 21287
23Antidepressive AgentsPhase 4, Phase 22666
24Neurotransmitter Uptake InhibitorsPhase 4, Phase 3, Phase 23464
25Neurotransmitter AgentsPhase 4, Phase 3, Phase 217734
26Muscarinic AntagonistsPhase 4, Phase 21134
27ParasympatholyticsPhase 4, Phase 21050
28Cytochrome P-450 CYP2D6 InhibitorsPhase 4716
29Sodium Channel BlockersPhase 41515
30calcium channel blockersPhase 41940
31AnticonvulsantsPhase 4, Phase 32620
32Calcium, DietaryPhase 45525
33Diuretics, Potassium SparingPhase 41827
34Excitatory Amino AcidsPhase 41297
35Excitatory Amino Acid AntagonistsPhase 41282
36Omega 3 Fatty AcidNutraceuticalPhase 4969
37
Naltrexoneapproved, investigational, vet_approvedPhase 3, Phase 237816590-41-35360515
Synonyms:
16590-41-3
16676-29-2
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one
BIDD:GT0405
BPBio1_000146
BRD-K88172511-310-03-8
BRN 3596648
BSPBio_000132
C07253
CCRIS 3506
CHEBI:121459
CHEBI:7465
CHEMBL142
CID5360515
Celupan
D05113
DB00704
Depade
EINECS 240-649-9
EN-1639A
HMS2089O11
HS-0002
HSDB 6750
LS-92094
MLS002153483
MolPort-004-920-221
 
MorViva
N-Cyclopropylmethyl-14-hydroxydihydromorphinone
N-Cyclopropylmethylnoroxymorphone
Naltrexon
Naltrexona
Naltrexona [INN-Spanish]
Naltrexone
Naltrexone (USAN/INN)
Naltrexone Hcl
Naltrexone [USAN:BAN:INN]
Naltrexone [USAN:INN:BAN]
Naltrexone [Usan:Ban:Inn]
Naltrexonum
Naltrexonum [INN-Latin]
PDSP2_000847
PTI-555
Prestwick0_000116
Prestwick1_000116
Prestwick2_000116
Prestwick3_000116
ReVia
SMP1_000206
SPBio_002071
UM-792
UNII-5S6W795CQM
Vivitrex
Vivitrol
Vivitrol (TN)
naltrexone
naltrexone (ReVia)
38
EthanolapprovedPhase 3, Phase 2204364-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
39
Olanzapineapproved, investigationalPhase 3395132539-06-14585
Synonyms:
132539-06-1
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC-665
AC1L1IHS
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
LS-152313
LY 170053
LY-170052
 
LY-170053
Lanzac
Lilly brand of olanzapine
MLS000759457
MLS001165781
MLS001195646
MLS001424057
Midax
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
Olanzapina
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa Zydis
olanzapina
olanzapine
olanzapinum
40
Selegilineapproved, investigational, vet_approvedPhase 32714611-51-926757, 5195
Synonyms:
(-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine
(-)-Deprenil
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
(R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine
(R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin
(−)-selegiline
14611-51-9
14611-52-0 (hydrochloride)
2079-54-1 (deprenyl.hydrochloride)
AC1L1BTZ
AC1Q2860
AKOS000281115
Anipryl
Apo-Selegiline
BPBio1_000687
BRD-K86434416-001-02-7
BRD-K86434416-003-03-1
BSPBio_000623
BSPBio_001589
C07245
C13H17N
CHEBI:9086
CHEMBL972
CID26757
Carbex
D03731
DB01037
Deprenyl
Eldepryl
Emsam
Emsam (TN)
Gen-Selegiline
HMS1791P11
HMS1989P11
HMS2089D09
Humex
 
Jumex
L-Deprenalin
L-Deprenyl
LS-30156
MolPort-000-883-771
N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine
N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine
NCGC00024994-01
NCGC00024994-02
NCGC00024994-03
NCGC00024994-04
Novo-Selegiline
Nu-Selegiline
Prestwick0_000552
Prestwick1_000552
Prestwick2_000552
Prestwick3_000552
SPBio_002544
STK640578
Sd Deprenyl
Selegeline Hcl
Selegilina
Selegilina [INN-Spanish]
Selegiline (USAN/INN)
Selegiline Transdermal System (STS) patch
Selegiline [INN:BAN]
Selegiline, (R)-Isomer
Selegilinum
Selegilinum [INN-Latin]
Selegyline
Tocris-1095
UNII-2K1V7GP655
Yumex
ZINC19632633
Zelapar
l-E 250
selegiline
41Anti-Infective Agents, LocalPhase 3, Phase 21785
42Quetiapine FumaratePhase 3, Phase 2413111974-72-2
43Protective AgentsPhase 3, Phase 2, Phase 17190
44Anti-Infective AgentsPhase 3, Phase 2, Phase 121402
45NarcoticsPhase 3, Phase 23486
46AntiemeticsPhase 33888
47Narcotic AntagonistsPhase 3, Phase 2906
48Gastrointestinal AgentsPhase 38109
49
Oxytocinapproved, vet_approvedPhase 2, Phase 140850-56-6439302, 53477758
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
(Arg8)-Vasopressin
(Arg8)-Vasotocin
1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
50-56-6
AC1L9735
Argipressin
Argpressin Acetate
BCBcMAP01_000094
Biotinyl-(Arg8)-Vasopressin
C00746
CHEBI:492195
CHEBI:7872
CHEMBL395429
CID439302
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Cys-Tyr-Ile-Thr-Asn-Cys-Gly-Leu-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2
D00089
Disulfide bridge Cys1-Cys6
Gly-Leu-Pro-c
HS-2021
 
L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
MolPort-003-938-941
NCGC00167132-01
O3251_SIGMA
O4375_SIGMA
OXT
OXYTOCIN
Ocytocin
Oxitocina
Oxytocic hormone
Oxytocin (JP15/USP/INN)
Oxytocin (TN)
Oxytocin 10 Usp Units In Dextrose 5%
Oxytocin 20 Usp Units In Dextrose 5%
Oxytocin 5 Usp Units In Dextrose 5%
Oxytocin Acetate
Oxytocin injection
Oxytocine
Oxytocinum
Pitocin
Pitocin (TN)
Syntocinon
Syntocinon (TN)
TI-001
alpha-Hypophamine
nchembio.184-comp2
50
AcetylcysteineapprovedPhase 2, Phase 1316616-91-112035
Synonyms:
(2R)-2-acetylamino-3-Sulfanylpropanoic acid
(R)-2-acetylamino-3-Mercaptopropanoic acid
(R)-Mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
 
Fluprowit
L-Acetylcysteine
L-alpha-acetamido-beta-Mercaptopropionic acid
Lysox
Mercapturic acid
Mucolysin
Mucomyst
N-ACETYL-L-cysteine
N-Acety-L-Cysteine
N-Acetyl-3-mercaptoalanine
N-Acetyl-L-(+)-cysteine
N-Acetylcysteine
N-acetylcysteine
NAC
Parvolex
Sodium 2-acetamido-3-mercaptopropionate

Interventional clinical trials:

(show top 50)    (show all 126)
idNameStatusNCT IDPhase
1Efficacy of Omega-3 Fatty Acids on Borderline Personality DisorderUnknown statusNCT00437099Phase 4
2Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality DisorderUnknown statusNCT00834834Phase 4
3Study of Lamotrigine Treatment of Affective Instability in Borderline Personality DisorderCompletedNCT00634062Phase 4
4Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality DisorderCompletedNCT00533117Phase 4
5Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality DisorderCompletedNCT00204347Phase 4
6Effects of Comorbid Personality Disorder on the Treatment of Bipolar I DisorderCompletedNCT00178061Phase 4
7BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality DisorderCompletedNCT00538135Phase 3
8Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)CompletedNCT00880919Phase 3
9Quetiapine Treatment for Symptoms Associated With Borderline Personality DisorderCompletedNCT00122070Phase 3
10Olanzapine in Patients With Borderline Personality DisorderCompletedNCT00091650Phase 3
11Efficacy and Safety of Olanzapine in Patients With Borderline Personality DisorderCompletedNCT00088036Phase 3
12Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality DisorderCompletedNCT01912391Phase 3
13Efficacy of Dialectical Behavior Therapy in Patients With Borderline Personality DisorderActive, not recruitingNCT01952405Phase 3
14Naltrexone in Borderline Personality DisorderTerminatedNCT00124839Phase 3
15Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol DependenceWithdrawnNCT00463775Phase 3
16Ziprasidone in the Treatment of Borderline Personality DisorderCompletedNCT00635921Phase 2
17Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder TreatmentCompletedNCT02125942Phase 1, Phase 2
18Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality DisorderCompletedNCT01103180Phase 2
19Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered PatientsCompletedNCT00254748Phase 2
20Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use DisorderCompletedNCT00145678Phase 2
21Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality DisorderCompletedNCT01133301Phase 2
22Treating PTSD in Patients With Borderline Personality DisorderCompletedNCT01081314Phase 1, Phase 2
23Treatment of Suicidal Women With Borderline Personality DisorderCompletedNCT00183651Phase 2
24Effectiveness of Group Based Schema Therapy in the Treatment of Personality DisordersCompletedNCT00247234Phase 2
25Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder SymptomsCompletedNCT01189812Phase 2
26Oxytocin as Adjunctive Therapy for SchizophreniaCompletedNCT01699997Phase 2
27Cognitive Therapy for PTSD in Addiction TreatmentCompletedNCT00685451Phase 1, Phase 2
28Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)RecruitingNCT02728778Phase 2
29A Novel Drug for Borderline Personality DisorderRecruitingNCT02097706Phase 2
30Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)RecruitingNCT01212588Phase 2
31Acetaminophen and Social ProcessesActive, not recruitingNCT02108990Phase 2
32Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood DisordersNot yet recruitingNCT02824627Phase 2
33N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPDTerminatedNCT00539188Phase 2
34College Students Who Self-HarmWithdrawnNCT02522143Phase 2
35Creativity Group for Borderline Personality DisorderUnknown statusNCT01343550Phase 1
36Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress DisorderUnknown statusNCT00269139Phase 1
3720 Weeks DBT Group Skills Training StudyCompletedNCT01193205Phase 1
38Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in AdolescentsCompletedNCT01111734Phase 1
39Examining Dose-Related Effects of Oxytocin on Social Cognition Across PopulationsRecruitingNCT02149823Phase 1
40Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality DisorderUnknown statusNCT01602497
41Event Related Potentials in Borderline Personality Disorder and Major DepressionUnknown statusNCT01469663
42Guanfacine to Treat Borderline Personality DisorderUnknown statusNCT00358969
43Promoting Recovery Processes in Women With Borderline Personality Disorder Using a Dynamic Cognitive InterventionUnknown statusNCT01531634
44Cognitive Therapy Versus Supportive Therapy in Borderline Personality DisorderUnknown statusNCT00131781
45A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality DisorderUnknown statusNCT01033708
46DBT in Borderline Personality DisorderUnknown statusNCT00252031
47A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy AdultsUnknown statusNCT01426984
48DBT and Escitalopram in Borderline Personality DisorderUnknown statusNCT00255554
49Evaluation of a Modified Dialectical Behavior Therapy ProgramUnknown statusNCT01635556
50Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality DisorderUnknown statusNCT01683136

Search NIH Clinical Center for Borderline Personality Disorder


Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

About this section

Anatomical Context for Borderline Personality Disorder

About this section

MalaCards organs/tissues related to Borderline Personality Disorder:

35
Brain, Amygdala, Bone, Testes, Cortex, Pituitary, Ovary

Animal Models for Borderline Personality Disorder or affiliated genes

About this section

MGI Mouse Phenotypes related to Borderline Personality Disorder:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107718.8BDNF, HTR2C, NR3C1, SLC6A4, TPH1, TPH2
2MP:00053698.3AVPR1A, HTR1B, HTR2A, HTR2C, NR3C1, SLC6A4
3MP:00053798.3AVPR1A, BDNF, COMT, HTR1B, HTR2A, NR3C1
4MP:00053857.6AVPR1A, COMT, HTR1A, HTR1B, MAOA, NR3C1
5MP:00053767.1AVPR1A, BDNF, COMT, HTR1A, HTR2C, MAOA
6MP:00036316.6AVPR1A, BDNF, COMT, HTR1A, HTR2C, MAOA
7MP:00053866.4AVPR1A, BDNF, COMT, HTR1A, HTR1B, HTR2A

Publications for Borderline Personality Disorder

About this section

Articles related to Borderline Personality Disorder:

(show top 50)    (show all 698)
idTitleAuthorsYear
1
Borderline personality disorder and compulsive buying: A multivariate etiological model. (27124503)
2016
2
Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: A two-years follow-up. (27107668)
2016
3
Differences in the association between childhood trauma history and borderline personality disorder or attention deficit/hyperactivity disorder diagnoses in adulthood. (27658669)
2016
4
The impact of stimulus arousal level on emotion regulation effectiveness in borderline personality disorder. (27203152)
2016
5
Integrating Early Intervention for Borderline Personality Disorder and Mood Disorders. (27144298)
2016
6
Experiences of family carers of people diagnosed with borderline personality disorder. (25857849)
2015
7
Incision and stress regulation in borderline personality disorder: neurobiological mechanisms of self-injurious behaviour. (25906795)
2015
8
Social feedback processing in borderline personality disorder. (26467724)
2015
9
Association between dopa decarboxylase gene variants and borderline personality disorder. (25017620)
2014
10
Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. (25356633)
2014
11
Associations Between Changes in Normal Personality Traits and Borderline Personality Disorder Symptoms Over 16 Years. (25364942)
2014
12
Emotional cascades as prospective predictors of dysregulated behaviors in borderline personality disorder. (23046043)
2013
13
Distinguishing bipolar II depression from major depressive disorder with comorbid borderline personality disorder: demographic, clinical, and family history differences. (24107761)
2013
14
Getting the word out about treating borderline personality disorder: an online information resource. (23334680)
2013
15
Trait anxiety modulates fronto-limbic processing of emotional interference in borderline personality disorder. (23459637)
2013
16
Psychological pathways from childhood sexual and physical abuse to HIV/sexually transmitted infection outcomes among homeless women: the role of posttraumatic stress disorder and borderline personality disorder symptoms. (23180873)
2013
17
Symptoms of borderline personality disorder predict interpersonal (but not independent) stressful life events in a community sample of older adults. (23713502)
2013
18
Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: A study of the association with valproic acid. (24196948)
2013
19
Personality disorders as maladaptive, extreme variants of normal personality: borderline personality disorder and neuroticism in a substance using sample. (24044664)
2013
20
Borderline personality disorder and emotional intelligence. (23364117)
2013
21
Multimodal examination of emotion regulation difficulties as a function of co-occurring avoidant personality disorder among women with borderline personality disorder. (24378158)
2013
22
Treatment of borderline personality disorder and co-occurring anxiety disorders. (23710329)
2013
23
The borderline empathy paradox: evidence and conceptual models for empathic enhancements in borderline personality disorder. (23514182)
2013
24
Borderline personality disorder in adolescents: the He-who-must-not-be-named of psychiatry. (24174891)
2013
25
The effect of anger rumination in the relationship between borderline personality disorder symptoms and precursors. (23586935)
2013
26
Alexithymia as a mediator between attachment and the development of borderline personality disorder in adolescence. (23013337)
2012
27
Gender Differences in a Clinical Sample of Patients with Borderline Personality Disorder. (22494170)
2012
28
Management of borderline personality disorder. (23027916)
2012
29
Borderline Personality Disorder (BPD) diagnosis with the self-report Personality Diagnostic Questionnairea894+(PDQ-4+): confirmation of the 3-factor structure. (22508070)
2012
30
An Empirical Examination of Gunderson's Proposed Revision of the Diagnostic Algorithm for Borderline Personality Disorder. (22984857)
2012
31
Affective startle modulation in incarcerated women with borderline personality disorder features. (22452769)
2012
32
Patient factors predicting early dropout from psychiatric outpatient care for borderline personality disorder. (22503328)
2012
33
Stress Regulation and Incision in Borderline Personality Disorder-A Pilot Study Modeling Cutting Behavior. (22616773)
2012
34
Predicting borderline personality disorder features from personality traits, identity orientation, and attachment styles in Italian nonclinical adults: issues of consistency across age ranges. (22486456)
2012
35
Adult attachment to transitional objects and borderline personality disorder. (22486448)
2012
36
A growth curve analysis of emotion dysregulation as a mediator for violence in individuals with and without borderline personality disorder. (22686232)
2012
37
Exploring the interface of neurobehaviorally linked personality dimensions and personality organization in borderline personality disorder: the Multidimensional Personality Questionnaire and Inventory of Personality Organization. (23281675)
2012
38
Children of mothers with borderline personality disorder: identifying parenting behaviors as potential targets for intervention. (22299065)
2012
39
Borderline personality disorder features and mate retention tactics. (22686222)
2012
40
Stress regulation and incision in borderline personality disorder--a pilot study modeling cutting behavior. (22867510)
2012
41
Behavioural treatment of severe chronic self-loathing in people with borderline personality disorder. Part 2: Self-compassion and other interventions. (23081999)
2012
42
Brain structure and function in borderline personality disorder. (22252376)
2012
43
The effect of ostracism upon mood in youth with borderline personality disorder. (22023305)
2011
44
Outcomes in women diagnosed with borderline personality disorder in adolescence. (21804844)
2011
45
Borderline personality disorder subscale (Chinese version) of the structured clinical interview for DSM-IV axis II personality disorders: a validation study in Cantonese-speaking Hong Kong Chinese. (21838207)
2011
46
A systematic review of interventions for co-occurring substance use disorder and borderline personality disorder. (21742460)
2011
47
Can negative attitudes toward patients with borderline personality disorder be changed? The effect of attending a STEPPS workshop. (22217226)
2011
48
Predisposition for borderline personality disorder with comorbid major depression is associated with that for polycystic ovary syndrome in female Japanese population. (22090801)
2011
49
Modulatory role of the brain-derived neurotrophic factor Val66Met polymorphism on the effects of serious life events on impulsive aggression in borderline personality disorder. (19817874)
2010
50
Borderline Personality Disorder, Bulimia Nervosa, Antisocial Personality Disorder, ADHD, Substance Use: Common Threads, Common Treatment Needs, and the Nature of Impulsivity. (21253443)
2010

Variations for Borderline Personality Disorder

About this section

Expression for genes affiliated with Borderline Personality Disorder

About this section
Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for genes affiliated with Borderline Personality Disorder

About this section

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 14)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.9COMT, MAOA
29.9COMT, MAOA
3
Show member pathways
9.9COMT, MAOA
49.8HTR2A, HTR2C
5
Show member pathways
9.7TPH1, TPH2
6
Show member pathways
9.6COMT, MAOA, TPH1
7
Show member pathways
9.4MAOA, SLC6A4, TPH2
8
Show member pathways
9.3BDNF, HTR1A, HTR1B
9
Show member pathways
9.0HTR1A, HTR1B, HTR2A, HTR2C
109.0COMT, HTR1A, TPH1, TPH2
118.9AVPR1A, HTR2A, HTR2C
127.7HTR1A, HTR1B, HTR2A, HTR2C, MAOA, SLC6A4
137.5BDNF, HTR1A, HTR2A, MAOA, NR3C1, SLC6A4
14
Show member pathways
7.4COMT, HTR1A, HTR1B, HTR2A, HTR2C, MAOA

GO Terms for genes affiliated with Borderline Personality Disorder

About this section

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1integral component of plasma membraneGO:00058877.3AVPR1A, HTR1A, HTR1B, HTR2A, HTR2C, NRXN3

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 26)
idNameGO IDScoreTop Affiliating Genes
1phospholipase C-activating serotonin receptor signaling pathwayGO:000720810.4HTR2A, HTR2C
2adenylate cyclase-inhibiting serotonin receptor signaling pathwayGO:000719810.4HTR1A, HTR1B
3serotonin metabolic processGO:004242810.4HTR1A, MAOA
4bone remodelingGO:004684910.4HTR1B, TPH1
5regulation of hormone secretionGO:004688310.4HTR1A, HTR2A
6neurotransmitter catabolic processGO:004213510.3COMT, MAOA
7positive regulation of phosphatidylinositol biosynthetic processGO:001051310.3HTR2A, HTR2C
8dopamine catabolic processGO:004242010.3COMT, MAOA
9aromatic amino acid family metabolic processGO:000907210.3TPH1, TPH2
10regulation of behaviorGO:005079510.1HTR1A, HTR1B, HTR2A
11indolalkylamine biosynthetic processGO:004621910.1TPH1, TPH2
12serotonin biosynthetic processGO:004242710.1TPH1, TPH2
13vasoconstrictionGO:004231010.0HTR1A, HTR1B, SLC6A4
14serotonin receptor signaling pathwayGO:000721010.0HTR1A, HTR2A, HTR2C
15sperm ejaculationGO:004271310.0AVPR1A, SLC6A4
16activation of phospholipase C activityGO:00072029.9AVPR1A, HTR2A
17behavioral fear responseGO:00016629.9HTR1A, HTR2C
18positive regulation of fat cell differentiationGO:00456009.9HTR2A, HTR2C, TPH1
19release of sequestered calcium ion into cytosolGO:00512099.8HTR2A, HTR2C
20circadian rhythmGO:00076239.8SLC6A4, TPH1, TPH2
21negative regulation of synaptic transmission, glutamatergicGO:00519679.8HTR1B, HTR2A
22positive regulation of vasoconstrictionGO:00459079.8AVPR1A, HTR2A
23regulation of dopamine secretionGO:00140599.7HTR1B, HTR2A
24chemical synaptic transmissionGO:00072688.8HTR1B, HTR2A, HTR2C, NRXN3, SLC6A4
25social behaviorGO:00351768.8AVPR1A, NRXN3, SLC6A4
26response to drugGO:00424938.5COMT, HTR1B, HTR2A, HTR2C, SLC6A4

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
11-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine bindingGO:007188610.3HTR2A, HTR2C
2tryptophan 5-monooxygenase activityGO:000451010.1TPH1, TPH2
3serotonin bindingGO:00513789.6HTR1B, HTR2A, HTR2C, MAOA
4amino acid bindingGO:00165979.6TPH1, TPH2
5G-protein coupled serotonin receptor activityGO:00049939.4HTR1A, HTR1B, HTR2A, HTR2C
6drug bindingGO:00081449.4HTR1B, HTR2A, HTR2C

Sources for Borderline Personality Disorder

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet